Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Rudin Discusses the Success of Immunotherapy in SCLC

Charles M. Rudin, MD, PhD
Published: Tuesday, Oct 30, 2018



Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer (SCLC).

This is an exciting time for SCLC, Rudin says, as new targets are emerging and new strategies are being deployed. One of the recent successes was with the PD-L1 inhibitor atezolizumab (Tecentriq). In patients with extensive-stage SCLC, the addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival compared with the chemotherapy regimen alone, according to findings from the IMpower133 trial.

The global, double-blind, randomized, placebo-controlled phase I/III IMpower133 study showed a clinically meaningful improvement in overall survival over the current standard of care for these patients. Rudin says although this is a positive study, the duration of response was not very long. There is still work being done to extend benefit though, and trials are ongoing, he adds.


Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer (SCLC).

This is an exciting time for SCLC, Rudin says, as new targets are emerging and new strategies are being deployed. One of the recent successes was with the PD-L1 inhibitor atezolizumab (Tecentriq). In patients with extensive-stage SCLC, the addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival compared with the chemotherapy regimen alone, according to findings from the IMpower133 trial.

The global, double-blind, randomized, placebo-controlled phase I/III IMpower133 study showed a clinically meaningful improvement in overall survival over the current standard of care for these patients. Rudin says although this is a positive study, the duration of response was not very long. There is still work being done to extend benefit though, and trials are ongoing, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x